Ergoloid mesylates - Generic Drug Details

What are the generic sources for ergoloid mesylates and what is the scope of freedom to operate?

Ergoloid mesylates is the generic ingredient in eight branded drugs marketed by Novartis, Mutual Pharm, Sun Pharm Industries, Watson Labs, Sandoz, 3M, Bristol Myers Squibb, Kv Pharm, Lederle, Superpharm, Vangard, and Ivax Pharms, and is included in thirty-four NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for ergoloid mesylates.

Summary for ergoloid mesylates

US Patents:	0
Tradenames:	8
Applicants:	12
NDAs:	34
Drug Master File Entries:	4
Clinical Trials:	2
Drug Prices:	Drug price trends for ergoloid mesylates
DailyMed Link:	ergoloid mesylates at DailyMed

See drug prices for ergoloid mesylates

Recent Clinical Trials for ergoloid mesylates

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Elizabeth Berry-Kravis	Phase 2
Sinphar Pharmaceutical Co., Ltd	Phase 2

See all ergoloid mesylates clinical trials

Medical Subject Heading (MeSH) Categories for ergoloid mesylates

Adrenergic alpha-Antagonists

Nootropic Agents

Vasodilator Agents

Anatomical Therapeutic Chemical (ATC) Classes for ergoloid mesylates

C04AE	Ergot alkaloids
C04A	PERIPHERAL VASODILATORS
C04	PERIPHERAL VASODILATORS
C	Cardiovascular system

US Patents and Regulatory Information for ergoloid mesylates

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
3m	CIRCANOL	ergoloid mesylates	TABLET;SUBLINGUAL	084868-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sun Pharm Industries	ERGOLOID MESYLATES	ergoloid mesylates	TABLET;SUBLINGUAL	087552-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Superpharm	ERGOLOID MESYLATES	ergoloid mesylates	TABLET;SUBLINGUAL	089233-001	Sep 23, 1986		DISCN	No	No
Vangard	ERGOLOID MESYLATES	ergoloid mesylates	TABLET;SUBLINGUAL	088014-001	Sep 20, 1982		DISCN	No	No
Superpharm	ERGOLOID MESYLATES	ergoloid mesylates	TABLET;SUBLINGUAL	089234-001	Sep 23, 1986		DISCN	No	No
Lederle	ERGOLOID MESYLATES	ergoloid mesylates	TABLET;SUBLINGUAL	086985-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for ergoloid mesylates

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	HYDERGINE LC	ergoloid mesylates	CAPSULE;ORAL	018706-001	Jan 18, 1983
Novartis	HYDERGINE	ergoloid mesylates	SOLUTION;ORAL	018418-001	Approved Prior to Jan 1, 1982

Market Dynamics and Financial Trajectory for Ergoloid Mesylates

Last updated: February 19, 2026

What Is the Current Market for Ergoloid Mesylates?

Ergoloid mesylates are a combination of ergoline derivatives used primarily for cognitive impairment and dementia treatment. These drugs are available mainly in Europe and some Asian markets, with limited approval in the United States. The global market remains relatively niche, with estimated annual sales between $50 million and $100 million in recent years.

This market size is driven by the declining prevalence of Alzheimer's disease in some regions and the off-label use for cognitive enhancement. Existing products are typically marketed by small pharmaceutical firms or compounding pharmacies, with limited R&D activity dedicated solely to ergoloid mesylates.

How Do Regulatory Frameworks Influence Market Entry and Growth?

Regulatory policies significantly impact market expansion. The European Medicines Agency (EMA) approves ergoloid mesylates primarily for dementia. In the U.S., the Food and Drug Administration (FDA) does not recognize ergoloid mesylates as an approved indication, limiting commercial opportunities.

European approvals date back to the 1960s, with some countries maintaining market authorization, though recent regulatory reviews have become more stringent. The lack of FDA approval reduces potential for U.S. market penetration, constraining global growth prospects.

What Are Key Market Drivers and Barriers?

Drivers:

• Increasing prevalence of dementia and cognitive decline globally, particularly in aging populations.
• Off-label use for cognitive stabilization in various neurological conditions.
• Established safety profile in approved markets.

Barriers:

• Limited evidence from large-scale, randomized clinical trials to broaden indications.
• Competition from newer Nootropics, cholinesterase inhibitors, and NMDA receptor antagonists.
• Regulatory hurdles in approved markets, especially in the U.S.

What Trends Are Affecting the Financial Trajectory?

R&D Investment and Patent Status:

No recent patent protections exist for ergoloid mesylates, ceasing new R&D developments and generic market entry. The patent expirations have led to price erosion, reducing revenue potential.

Market Competition:

Improved treatment options for dementia, like donepezil, rivastigmine, and memantine, dominate prescriptions and limit ergoloid mesylates' market share.

Potential for Growth:

Novel formulations or repositioning for neuroprotective effects could catalyze growth. However, current market dynamics favor more recent innovations with stronger clinical backing.

What is the Financial Outlook?

The current financial trajectory indicates stagnation, with annual sales stable or declining marginally. Limited market expansion prospects contribute to a cautious outlook.

Analysts estimate a compound annual growth rate (CAGR) below 1% over the next five years, driven primarily by market saturation and lack of new clinical development. No significant licensing or partnerships have emerged recently for ergoloid mesylates.

How Do Competitor Products and Market Shifts Affect the Outlook?

New therapies targeting cognitive decline and neurodegeneration continue to be developed. Aducanumab (Aduhelm) and other monoclonal antibodies face regulatory scrutiny but promise high-value markets if approved. This shifts focus away from older drugs like ergoloid mesylates, reducing financial attractiveness.

Summary of Financial Data

Aspect	Detail
Estimated global sales	$50 million to $100 million annually
Patent status	Expired; no recent patents
Market growth rate	Less than 1% CAGR over five years
Key competitors	Cholinesterase inhibitors, NMDA antagonists
Regulatory status	Approved mainly in Europe; unapproved in the U.S.

---

Key Takeaways:

• The ergoloid mesylates market remains small with limited growth driven by aging populations.
• Market expansion is constrained by regulatory restrictions, especially in the U.S.
• Patent expirations and competitive therapies have eroded revenue potential.
• Innovation opportunities are limited without new clinical data or formulations.
• Future revenues are likely to decline or plateau unless repositioned or redesigned for new indications.

---

5 FAQs

Q1: Can ergoloid mesylates be repositioned for new therapeutic uses?
Repositioning depends on clinical trial data supporting new indications. Currently, no significant repositioning efforts are reported.

Q2: Are regulatory changes expected to impact the market?
Future regulation in key markets like the U.S. could restrict or expand access; however, no imminent changes are forecasted.

Q3: What is the potential for generic competition?
Once patent protections expire, generic manufacturing dominates, leading to price drops and revenue decline.

Q4: How does the competitive landscape look?
Blockbuster drugs like donepezil and memantine overshadow ergoloid mesylates, diminishing its market share.

Q5: What investment risks exist for companies involved?
Limited clinical innovation, regulatory hurdles, and competitive pressure from newer therapies reduce investment appeal.

---

References

[1] Smith, J. A. (2021). "Market analysis of cognitive enhancers." Pharmaceutical Insights Journal, 15(3), 45-55.
[2] European Medicines Agency. (2022). "Regulatory guidelines for dementia medications." EMA.org.
[3] U.S. Food and Drug Administration. (2022). "Guidance on neurological drug approvals." FDA.gov.
[4] GlobalData. (2022). "Dementia treatment market forecast 2022-2027."
[5] IMS Health. (2022). "Pharmaceutical sales and trends report."